glp·helper
glphelper.com/ozempic/florida/ocoee
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Ocoee, FL

Verified Ozempic providers in Ocoee, FL. Checked against the NPI registry, never ranked by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
26
as of today
§ 02Provider directory: Florida
26 of 26 shown

Find an Ozempic provider in Florida.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Florida city · /ozempic/florida/{city}
§ 03Getting Ozempic in Ocoee
26 providers · Ocoee, FL

How to get Ozempic in Ocoee.

26 GLP-1 prescribers and 7 local resource types are on record for Ocoee, plus 3 nearby towns in the directory.

Prescribers in Ocoee
26 prescribers
26 GLP-1 prescribers in Ocoee, most listed as Family Medicine (13), Internal Medicine (10) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Apopka (21 providers), Altamonte Springs (23 providers) and Clermont (30 providers).
Around the prescription in Ocoee
7 listed nearby
11 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 5 places to move are on record near Ocoee.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Ocoee

Ocoee, Florida has a population of 47,295 people. The adult obesity rate in Ocoee is an age-adjusted estimate of 33.6%, 4 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 11.5% of adults in Ocoee. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 25.4% of adults in Ocoee.

of Ocoee adults have obesity
33.6%
diagnosed diabetes
11.5%
no regular physical activity
25.4%

Age-adjusted estimates for Ocoee, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Ozempic in Ocoee
6 fitness clubs

The prescription is one part. Here is the rest, in Ocoee.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Ocoee, FL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

City of Ocoee Jim Beech Recreation Center
REC CENTER
4.3 on Google · 251 reviews
1820 A D Mims Rd
Website
Planet Fitness
GYM
4.4 on Google · 1029 reviews
10908 W Colonial Dr
Website
Anytime Fitness
GYM
4.8 on Google · 242 reviews
9679 W Colonial Dr
Website
Smart Fitness
TRAINING
5.0 on Google · 161 reviews
324 Moore Rd
Website
Rhein Athletic Club
GYM
5.0 on Google · 124 reviews
13367 W Colonial Dr
Website
Iron Core Gym
GYM
4.9 on Google · 100 reviews
491 W Silver Star Rd
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Michael Arp, MS
RD
Registered dietitian
10000 W Colonial Dr
Call 407-296-1022NPI 1679179055
Janice Bader, RD,LD/N
RD
Registered dietitian
10000 W Colonial Dr
Call 407-297-8408NPI 1528247467
Lori Bondurant, RDN LDN CSCS
RD
Registered dietitian
450 Darkwood Ave
Call 407-579-6649NPI 1558227660
Stephanie Hanley, RD
RD
Registered dietitian
2710 Rew Cir
Call 888-644-1884NPI 1790466506
Allison Harrell, RDN, CCMS
RD
Registered dietitian
129 Nw 13Th St Ste 20
Call 321-438-6444NPI 1316282353
Mary Mandry, RD, LD/N
RD
Registered dietitian
1510 Citrus Medical Ct
Call 407-480-4830NPI 1689188385
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Florida

NPI-verified Ozempic (semaglutide) prescribers and clinics, never ranked by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]